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Elimination of lymphatic ﬁlariasis: The
endgame and challenges for meeting the 2020
target
B. Koudou
Liverpool School of Tropical Medicine, Liverpool,
United Kingdom
Lymphatic ﬁlariasis (LF) is a major cause of acute and chronic
morbidity and a signiﬁcant impediment to socioeconomic devel-
opment in 73middle and low income countries. The disease affects
120 million people and a further 1.4 billion are also at risk of
acquiring the disease through exposure to mosquito bites. It has
been estimated that eliminating LF can provide economic bene-
ﬁts in excess of US$22 billion over an 8-year period. The Global
Programme to Eliminate Lymphatic Filariasis (GPELF) through the
WHO strategy of preventive chemotherapy and transmission con-
trol (PCT), has targeted LF for elimination by 2020. This will be
achieved mainly by mass drug administration (MDA) of albenda-
zole in combination with either ivermectin or diethylcarbamazine
citrate (DEC). PCT is a pro-poor strategy that enables regular and
coordinated administration of safe, single-dosemedications. GPELF
is one of the most rapidly expanding global health programs in the
history of public health administeringmore than 540million treat-
ments in 54 countries in 2012. The MDA campaign has been most
effective in the middle-income economies of Southeast Asia where
all 15 endemic countries have initiated MDA. In Africa, only 18 of
the 34 endemic countries were implementing MDA in 2012. Many
of the communities in countries yet to start MDA for LF elimination
are in hard to reach areas in post-conﬂict environments with poor
health systems infrastructure. Following several annual rounds
since GPELF was launched in 2000, many countries are now scal-
ing down MDA activities after achieving 100% geographic coverage
and instituting monitoring and evaluation procedures to establish
the impact of several consecutive rounds of MDA and determine
if transmission has been interrupted. At the same time, countries
yet to initiate MDA will have to adopt improved mapping and cov-
erage assessment protocols to accelerate the efforts for achieving
global elimination by 2020. There are other challenges have to
be addressed if the 2020 target is to be achieved. Nevertheless,
PCT presents an excellent platform for integrated control of other
neglected tropical diseases (NTDs) where several diseases coexist,
given that either or both ivermectin and albendazole are effective
against onchocerciasis and soil-transmitted helminthiasis.
http://dx.doi.org/10.1016/j.ijid.2014.03.503
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Trachoma control & elimination in Africa
T. Gebre
International Trachoma Initiative, Addis Ababa,
Ethiopia
Trachoma is aneglected tropicaldiseaseandremains theworld’s
leading infectious cause of blindness. Overall, it is the eighth
commonest blinding disease. Trachoma is caused by the obli-
gate intracellular bacterium C. trachomatis. Recurrent episodes
of conjunctival infection and the associated chronic inﬂamma-
tion it causes initiate a scarring process that ultimately leads to
irreversible blindness. Blinding trachoma is prevalent in many of
the poorest and most remote rural areas in 53 countries in Africa,
Asia, Central America and SouthAmerica, Australia and theMiddle-
East. Overall, Africa is the most badly affected continent with 18.2
million cases of active trachoma (85.3% of all cases globally) and
3.2 million cases of trichiasis (44.1% of all cases globally) occur-
ring in 29 of the 46 countries in WHO’s African Region. Nearly
half of the global disease burden of active trachoma and a quar-
ter of end stage trichiasis are concentrated in ten countries with
six of these located in SSA. Ethiopia has the highest number of
cases (10.2 million) followed by Republic of South Sudan (3.6 mil-
lion) and Tanzania, Kenya, and Niger (about two million each).
The burden of trachoma is measured not just in the prevalence,
nor in the prevalence of blindness or visual loss due to trachoma.
The prevalent cases of visual loss are responsible for 39 million
lifetime disability-adjusted life years (DALYs). In a recent WHO
report (2013), the annual economic cost of trachoma in terms
of lost productivity is estimated to be between US$ 2.9 billion
and US$ 5.3 billion, increasing to US$ 8 billion when trichiasis is
included. Based on the current understanding of the epidemiology
of trachoma and its risk factors, the WHO has endorsed what is
known as the SAFE (Surgery, Antibiotics, Facial hygiene, Environ-
mental sanitation) strategy for countries implementing trachoma
control programs. The SAFE Strategy is an innovative public health
approach designed to treat and prevent trachoma.
A lot has been achieved in the African region over the past
several years in mapping (Global Trachoma Mapping Project),
planning (Trachoma Action Plan) and implementation of interven-
tions (SAFE), advancingknowledgeof trachoma throughoperations
researchandclinical trials. Thispaper attempts topresent summary
of key achievements in the run up to Global Elimination of blinding
Trachoma by 2020 also known as GET2020.
http://dx.doi.org/10.1016/j.ijid.2014.03.504
